A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad") cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses.
CRISPR Gene-Editing Therapy Shows Promise in Reducing Cholesterol in Human Trials
A clinical trial by Cleveland Clinic demonstrated that a one-time CRISPR-Cas9 gene-editing therapy effectively and safely reduced LDL cholesterol and triglycerides in patients with medication-resistant lipid disorders over a year. This advancement in gene therapy could have implications for healthcare innovations in Iran, particularly in addressing lipid disorders. The success of such therapies may influence Iran's approach to modern medical treatments.
👥 Key Players
📰 What Happened
A clinical trial conducted by the Cleveland Clinic demonstrated that a one-time infusion of CRISPR-Cas9 gene-editing therapy effectively and safely reduced LDL cholesterol and triglycerides in patients with lipid disorders resistant to medication over a year.
- The trial involved human participants with medication-resistant lipid disorders.
- The therapy showed effectiveness across all doses tested.
💡 Why It Matters
📚 Background
CRISPR-Cas9 is a groundbreaking gene-editing technology that allows for precise modifications to DNA, offering potential cures for genetic disorders.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%